Referencing for people who value simplicity, privacy, and speed.Get Citationsy
← Back to Search
Biochemical Recurrence After Radical Prostatectomy With Or Without Pelvic Lymphadenectomy In Korean Men With High-risk Prostate Cancer.
Published 2011 · Medicine
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
OBJECTIVE To identify predictors of biochemical recurrence (BCR) after radical prostatectomy with or without standard pelvic lymphadenectomy in Korean men with high-risk prostate cancer. METHODS The clinical and pathologic data of 199 patients with high-risk features were reviewed retrospectively. High-risk features were prostate-specific antigen level >20 ng/ml, biopsy Gleason score ≥8 or clinical tumor category ≥2c. All patients were followed up by measuring their prostate-specific antigen levels every 3 months. The median follow-up period was 37.0 months (range: 1.0-143.0). RESULTS During the follow-up period, biochemical recurrence was observed in 68 patients (34.2%). The 1-, 3- and 5-year biochemical recurrence-free survival rates were 79.6, 61.9 and 49.2%, respectively. Surgical Gleason score ≥8, positive surgical margin, extracapsular extension, and seminal vesicle invasion correlated significantly with biochemical recurrence-free survival (all P < 0.05), but pelvic lymphadenectomy did not. Multivariate Cox's proportional hazard analysis revealed that the only significant independent prognostic factor of biochemical recurrence-free survival was seminal vesicle invasion (P = 0.035, relative risk = 1.81). CONCLUSIONS Men with seminal vesicle invasion appear to have a significantly higher biochemical recurrence risk in patients with high-risk prostate cancer. However, since the natural history of prostate cancer is variable and accurate means of identifying those who will progress are currently available, it will be necessary to conduct further studies to find prognostic parameters that will allow the early identification of high-risk patients who could benefit from early salvage or adjuvant therapy.